Literature DB >> 18220940

Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis.

Andreas Schäfer1, Johann Bauersachs.   

Abstract

Platelet activation induces rapid thrombus formation at a ruptured atherosclerotic plaque leading to acute vessel occlusion and a fatal or non-fatal cardiovascular event. More recent evidence suggests that activated platelets play an additional central role during the initiation of atherosclerosis, essentially facilitating leukocyte adhesion and recruitment. Endothelial dysfunction is a common and early feature of cardiovascular diseases characterized by reduced bioavailability of prostacyclin and nitric oxide (NO). Subsequently impaired endogenous platelet inhibition causes platelet activation in pre-atherosclerotic vascular disease resulting in enhanced platelet susceptibility to agonists released from the inflamed endothelium. Platelet adhesion to inflammatory, dysfunctional endothelium precedes leukocyte adhesion. Indeed, adherent activated platelets are mandatory for leukocyte recruitment in the early phases of atherosclerosis under arterial flow conditions. Increased expression of chemokines in atherosclerotic plaques and the inflamed endothelium initiates and facilitates pro-inflammatory processes in leukocytes and the vascular wall. Apart from their chemotactic properties, some chemokines such as fractalkine contribute to platelet activation. Moreover, fractalkine induces leukocyte recruitment to inflamed endothelial cells under arterial flow by activating adherent platelets. An aggressive form of atherosclerosis is found in patients with diabetes. Since diabetes is currently considered as a risk equivalent for coronary artery disease, the interaction between oxidative stress, endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation is discussed in the light of diabetes. Defective regulation of platelet activation/aggregation is a predominant cause for arterial thrombosis, the major complication of atherosclerosis triggering myocardial infarction and stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220940     DOI: 10.2174/157016108783331295

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  35 in total

1.  A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters.

Authors:  Vishal Singh; Manish Jain; Prem Prakash; Ankita Misra; Vivek Khanna; Rajiv Lochan Tiwari; Ravi Shankar Keshari; Shivendra Singh; Madhu Dikshit; Manoj Kumar Barthwal
Journal:  J Physiol Biochem       Date:  2011-02-01       Impact factor: 4.158

Review 2.  Cerebral malaria: we have come a long way.

Authors:  Henry J Shikani; Brandi D Freeman; Michael P Lisanti; Louis M Weiss; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Am J Pathol       Date:  2012-09-25       Impact factor: 4.307

3.  The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome.

Authors:  M A Yilmaz; C Duran; M Basaran
Journal:  J Endocrinol Invest       Date:  2015-06-23       Impact factor: 4.256

Review 4.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

5.  Overexpressed eNOS upregulates SIRT1 expression and protects mouse pancreatic β cells from apoptosis.

Authors:  Tingting Hu; Ye Chen; Qian Jiang; Jun Lin; Hewei Li; Ping Wang; Leping Feng
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447

6.  Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.

Authors:  Amal Hofni; Basim A Shehata Messiha; Safwat A Mangoura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-11       Impact factor: 3.000

Review 7.  Effect of cilostazol in treating diabetes-associated microvascular complications.

Authors:  Nicole J Asal; Karolina A Wojciak
Journal:  Endocrine       Date:  2017-03-14       Impact factor: 3.633

8.  Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response.

Authors:  Dong-Mee Lim; Keun-Young Park; Won-Min Hwang; Ju-Young Kim; Byung-Joon Kim
Journal:  Exp Ther Med       Date:  2017-03-29       Impact factor: 2.447

9.  Factors contributing to increased platelet reactivity in people with diabetes.

Authors:  David J Schneider
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

10.  Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation.

Authors:  Sahru Yüksel; Lilit Ayvazyan; Armen Yuri Gasparyan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.